Oppenheimer Downgrades ESSA Pharma(EPIX.US) to Hold Rating

奥本海默控股下调ESSA Pharma(EPIX.US)至持有评级

moomoo资讯 · 11/04 18:33 · 评级/大行评级

Oppenheimer analyst Leland Gershell downgrades $ESSA Pharma (EPIX.US)$ to a hold rating.

According to TipRanks data, the analyst has a success rate of 37.3% and a total average return of 3.4% over the past year.

AnalystRecentRatingAutoNews_211178_20241103_f179da8a562503389544bb9cc03d86d30d7702dc_1730716364403816_mm_en

Furthermore, according to the comprehensive report, the opinions of $ESSA Pharma (EPIX.US)$'s main analysts recently are as follows:

Essa Pharma has decided to cease all development of masofaniten after a predetermined futility analysis indicated the candidate did not achieve the desired efficacy profile in the Phase 2 enzalutamide combination study. The company is now initiating a strategic process to explore options that would best enhance shareholder value, details of which are anticipated.
Essa Pharma has halted all masofaniten programs after an interim analysis from its Phase 2 trial, which did not demonstrate any advantage of combining maso with enza over enza alone in treating metastatic castration-resistant prostate cancer. Analysts note the update is unfortunate, but commend the company for its swift action to cease these programs and consider strategic alternatives. Concerns have been raised regarding the company's future direction and the absence of additional assets at various stages of development.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

奥本海默控股分析师Leland Gershell下调$ESSA Pharma (EPIX.US)$至持有评级。

根据TipRanks数据显示，该分析师近一年总胜率为37.3%，总平均回报率为3.4%。

AnalystRecentRatingAutoNews_211178_20241103_f179da8a562503389544bb9cc03d86d30d7702dc_1730716364403816_mm_sc

此外，综合报道，$ESSA Pharma (EPIX.US)$近期主要分析师观点如下：

essa pharma已决定停止所有masofaniten的开发，因为预定的无效分析表明该候选药在第2阶段enzalutamide联合研究中未达到期望的疗效特征。该公司现在正在启动战略流程，探讨最能增强股东价值的选择，详细信息预计将在后续公布。
essa pharma已在第2阶段试验的中期分析后停止了所有masofaniten项目，这一分析未显示将maso与enza与enza单独结合治疗转移性去势抵抗性前列腺癌方面有任何优势。分析师指出更新令人遗憾，但赞赏公司迅速行动停止这些项目并考虑战略替代方案。人们对公司未来方向以及在各个发展阶段缺乏其他资产的担忧逐渐增加。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Oppenheimer Downgrades ESSA Pharma(EPIX.US) to Hold Rating

Oppenheimer Downgrades ESSA Pharma(EPIX.US) to Hold Rating

风险及免责提示

声明